{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:15:57Z","timestamp":1770174957025,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline Construction","award":["TJYXZDXK-3-006B"],"award-info":[{"award-number":["TJYXZDXK-3-006B"]}]},{"name":"the National Science and Technology Innovation 2030, Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["Grant No. 2024ZD0524300, 2024ZD0524301"],"award-info":[{"award-number":["Grant No. 2024ZD0524300, 2024ZD0524301"]}]},{"name":"Tianjin Municipal Research Project in Priority Areas of Traditional Chinese Medicine","award":["2022011"],"award-info":[{"award-number":["2022011"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470527"],"award-info":[{"award-number":["82470527"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2024RC004, TJWJ2022MS009"],"award-info":[{"award-number":["TJWJ2024RC004, TJWJ2022MS009"]}]},{"name":"Key Science and Technology Support Project of Tianjin Science and Technology Bureau","award":["24ZXGZSY00130"],"award-info":[{"award-number":["24ZXGZSY00130"]}]},{"name":"Key Research Project of Tianjin Education Commission","award":["2024ZD031"],"award-info":[{"award-number":["2024ZD031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02844-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:25:12Z","timestamp":1767680712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy of statin and acipimox versus statin monotherapy in acute myocardial infarction with hypertriglyceridemia: a multicenter propensity score\u2013matched analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Tianshu","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengkai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-0738","authenticated-orcid":false,"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-6438","authenticated-orcid":false,"given":"Kang-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"14","key":"2844_CR1","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of Non-Statin therapies for LDL-Cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2844_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJM199304293281702","volume":"328","author":"MH Criqui","year":"1993","unstructured":"Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328(17):1220\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"2844_CR3","first-page":"100","volume":"9","author":"R Klempfner","year":"2016","unstructured":"Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, et al. Elevated triglyceride level is independently associated with increased All-Cause mortality in patients with established coronary heart disease. Circ: Cardiovasc Qual Outcomes. 2016;9(2):100\u20138.","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"key":"2844_CR4","doi-asserted-by":"publisher","unstructured":"Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y, Kochba I, Shai I. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147:377\u201385. https:\/\/doi.org\/10.7326\/0003-4819-147-6-200709180-00007.","DOI":"10.7326\/0003-4819-147-6-200709180-00007"},{"issue":"4","key":"2844_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease. Circulation. 2007;115(4):450\u20138.","journal-title":"Circulation"},{"key":"2844_CR6","doi-asserted-by":"crossref","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309\u201316.","DOI":"10.1001\/jama.298.3.309"},{"key":"2844_CR7","doi-asserted-by":"publisher","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299\u2013308. https:\/\/doi.org\/10.1001\/jama.298.3.299.","DOI":"10.1001\/jama.298.3.299"},{"issue":"1","key":"2844_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12944-024-02127-8","volume":"23","author":"C Hu","year":"2024","unstructured":"Hu C, Zhao Z, Dong S, Guo Q, Zhou Y. The clinical role of combined Circulating complement C1q and AIP for CAD with LDL-C level below 1.8mmol\/L. Lipids Health Dis. 2024;23(1):131.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"2844_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2169\/internalmedicine.53.1423","volume":"53","author":"Y Shimizu","year":"2014","unstructured":"Shimizu Y, Nakazato M, Sekita T, Koyamatsu J, Kadota K, Yamasaki H, et al. Association between hemoglobin and diabetes in relation to the Triglycerides-to-High-Density lipoprotein cholesterol (TG-HDL) ratio in Japanese individuals: the Nagasaki Islands study. Intern Med. 2014;53(8):837\u201343.","journal-title":"Intern Med"},{"issue":"47","key":"2844_CR10","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European atherosclerosis society. Eur Heart J. 2021;42(47):4791\u2013806.","journal-title":"Eur Heart J"},{"issue":"2","key":"2844_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.acvd.2020.11.006","volume":"114","author":"M Farnier","year":"2021","unstructured":"Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021;114(2):132\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"2844_CR12","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.jacl.2023.11.004","volume":"18","author":"M Zeller","year":"2024","unstructured":"Zeller M, Chague F, Maza M, Bichat F, Cottin Y, Farnier M. Characteristics and prognosis of patients with elevated triglycerides in acute myocardial infarction: observational data from a large database over a 17-year period. J Clin Lipidol. 2024;18(1):e38\u201343.","journal-title":"J Clin Lipidol"},{"key":"2844_CR13","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, NLA\/PCNA Guideline on the Management of Blood Cholesterol. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA. Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 June 18 [cited 2025 Oct 29];139(25) https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000624.","DOI":"10.1161\/CIR.0000000000000699"},{"issue":"9","key":"2844_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","volume":"78","author":"SS Virani","year":"2021","unstructured":"Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2844_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/dom.13921","volume":"22","author":"PP Toth","year":"2020","unstructured":"Toth PP, Fazio S, Wong ND, Hull M, Nichols GA. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes Obes Metab. 2020;22(3):279\u201389.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2844_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/med.20102","volume":"27","author":"W Soudijn","year":"2007","unstructured":"Soudijn W, van Wijngaarden I, IJzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev. 2007;27(3):417\u201333.","journal-title":"Med Res Rev"},{"key":"2844_CR17","doi-asserted-by":"crossref","unstructured":"Salvador C, Entenmann A, Salvador R, Niederwanger A, Crazzolara R, Kropshofer G. Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia. J Clin Lipidol. 2018;12(5):1260\u20136.","DOI":"10.1016\/j.jacl.2018.05.021"},{"issue":"2","key":"2844_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0031-6989(81)80017-3","volume":"13","author":"PP Lovisolo","year":"1981","unstructured":"Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) II \u2014 Antilipolytic and blood lipid Lowering activity. Pharmacol Res Commun. 1981;13(2):163\u201374.","journal-title":"Pharmacol Res Commun"},{"issue":"6","key":"2844_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/clpt.1980.236","volume":"28","author":"LM Fuccella","year":"1980","unstructured":"Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther. 1980;28(6):790\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"2844_CR20","doi-asserted-by":"crossref","unstructured":"Ahmed K. Biological Roles and Therapeutic Potential of Hydroxy-Carboxylic Acid Receptors. Front Endocrinol. 2011 Oct 25 [cited 2025 Oct 29];2. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2011.00051\/abstract.","DOI":"10.3389\/fendo.2011.00051"},{"issue":"42","key":"2844_CR21","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378.","journal-title":"Eur Heart J"},{"issue":"1","key":"2844_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"2844_CR23","doi-asserted-by":"crossref","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. 2025 : A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025 Apr [cited 2025 Apr 19];151(13). Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001309.","DOI":"10.1161\/CIR.0000000000001309"},{"key":"2844_CR24","doi-asserted-by":"publisher","unstructured":"Ren JY, Zhang H, Shao X, et al. Impact of PCSK9 inhibitors on bleeding and adverse outcomes in post-PCI patients undergoing antiplatelet therapy: A real-world cohort study. Int J Cardiol. 2025;434:133352. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133352.","DOI":"10.1016\/j.ijcard.2025.133352"},{"key":"2844_CR25","unstructured":"Zhang N, Gu T, Hu S, Liu T, Chen KY. PCSK9 inhibitor with cause-specific mortality amongst cancer survivors: a chance to kill two birds with one stone. Eur J Prev Cardiol. [cited 2024 Dec 28]; Available from: https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwae368\/7896200."},{"issue":"2","key":"2844_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamacardio.2020.4939","volume":"6","author":"E Ajufo","year":"2021","unstructured":"Ajufo E, Ayers CR, Vigen R, Joshi PH, Rohatgi A, de Lemos JA, et al. Value of coronary artery calcium scanning in association with the net benefit of aspirin in primary prevention of atherosclerotic cardiovascular disease. JAMA Cardiol. 2021;6(2):179.","journal-title":"JAMA Cardiol"},{"issue":"10132","key":"2844_CR27","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775\u201382.","journal-title":"Lancet"},{"issue":"2","key":"2844_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1074248413514481","volume":"19","author":"WE Boden","year":"2014","unstructured":"Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther. 2014;19(2):141\u201358.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"2844_CR29","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1194\/jlr.R040592","volume":"54","author":"WL Song","year":"2013","unstructured":"Song WL, FitzGerald GA. Niacin, an old drug with a new twist. J Lipid Res. 2013;54(10):2586\u201394.","journal-title":"J Lipid Res"},{"issue":"2","key":"2844_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0021-9150(01)00588-3","volume":"160","author":"M Pirro","year":"2002","unstructured":"Pirro M, Mauri\u00e8ge P, Tchernof A, Cantin B, Dagenais GR, Despr\u00e9s JP, et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Qu\u00e9bec cardiovascular study. Atherosclerosis. 2002;160(2):377\u201384.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2844_CR31","doi-asserted-by":"publisher","first-page":"H1220","DOI":"10.1152\/ajpheart.00475.2010","volume":"299","author":"M Halbirk","year":"2010","unstructured":"Halbirk M, N\u00f8rrelund H, M\u00f8ller N, Schmitz O, G\u00f8tzsche L, Nielsen R, et al. Suppression of Circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol-heart C. 2010;299(4):H1220\u20135.","journal-title":"Am J Physiol-heart C"},{"key":"2844_CR32","doi-asserted-by":"crossref","unstructured":"Espinoza-Derout J, Arambulo JML, Ramirez-Trillo W, Rivera JC, Hasan KM, Lao CJ et al. The lipolysis inhibitor acipimox reverses the cardiac phenotype induced by electronic cigarettes. Sci Rep. 2023;25:13(1). Available from: https:\/\/www.nature.com\/articles\/s41598-023-44082-x .[cited 2025 Oct 29]","DOI":"10.1038\/s41598-023-44082-x"},{"issue":"12","key":"2844_CR33","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.13384","volume":"83","author":"ET Vestergaard","year":"2017","unstructured":"Vestergaard ET, Cichosz SL, M\u00f8ller N, J\u00f8rgensen JOL, Fleischer J. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017;83(12):2671\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2844_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12944-024-02258-y","volume":"23","author":"X Feng","year":"2024","unstructured":"Feng X, Liu Y, Yang J, Zhou Z, Yang S, Zhou Y, et al. The prognostic role of remnant cholesterol in Asian menopausal women received percutaneous coronary intervention with acute coronary syndrome. Lipids Health Dis. 2024;23(1):276.","journal-title":"Lipids Health Dis"},{"key":"2844_CR35","doi-asserted-by":"crossref","unstructured":"Mc NHHJLDH, Jw Z, Jc D. B. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. J Intern Med. 1997 Feb [cited 2025 Oct 29];241(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9077372\/.","DOI":"10.1046\/j.1365-2796.1997.97112000.x"},{"issue":"1","key":"2844_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12944-024-02335-2","volume":"23","author":"X Feng","year":"2024","unstructured":"Feng X, Liu Y, Yang J, Yang S, Zhou Z, Zhou Y, et al. The combined predictive power of the atherogenic index of plasma and serum glycated albumin for cardiovascular events in postmenopausal patients with acute coronary syndrome after percutaneous coronary intervention. Lipids Health Dis. 2024;23(1):352.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"2844_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1365-2796.2002.00922.x","volume":"251","author":"HE YLI-JAMA P, MEYER","year":"2002","unstructured":"YLI-JAMA P, MEYER HE, PEDERSEN RINGSTADJ. Serum free fatty acid pattern and risk of myocardial infarction: a case\u2010control study. J Intern Med. 2002;251(1):19\u201328.","journal-title":"J Intern Med"},{"issue":"8347","key":"2844_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(83)90388-4","volume":"322","author":"MJB Tansey","year":"1983","unstructured":"Tansey MJB, Opie LH, RELATION BETWEEN PLASMA FREE FATTY ACIDS, AND ARRHYTHMIAS WITHIN THE FIRST TWELVE HOURS OF ACUTE MYOCARDIAL INFARCTION. Lancet. 1983;322(8347):419\u201322.","journal-title":"Lancet"},{"issue":"1","key":"2844_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbrc.2012.10.011","volume":"428","author":"F Jin","year":"2012","unstructured":"Jin F, Jiang S, Yang D, Zhang X, Yang Y, Zhang Y, et al. Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet. Biochem Biophys Res Commun. 2012;428(1):86\u201392.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2844_CR40","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/ATVBAHA.109.191304","volume":"29","author":"W Guo","year":"2009","unstructured":"Guo W, Wong S, Pudney J, Jasuja R, Hua N, Jiang L, et al. Acipimox, an inhibitor of Lipolysis, attenuates atherogenesis in LDLR-Null mice treated with HIV protease inhibitor Ritonavir. Arterioscler, thromb. Vasc Biol. 2009;29(12):2028\u201332.","journal-title":"Vasc Biol"},{"issue":"4","key":"2844_CR41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2337\/db14-0667","volume":"64","author":"T van de Weijer","year":"2015","unstructured":"van de Weijer T, Phielix E, Bilet L, Williams EG, Ropelle ER, Bierwagen A, et al. Evidence for a direct effect of the NAD\u2009+\u2009Precursor acipimox on muscle mitochondrial function in humans. Diabetes. 2015;64(4):1193\u2013201.","journal-title":"Diabetes"},{"issue":"2","key":"2844_CR42","doi-asserted-by":"publisher","first-page":"e076518","DOI":"10.1136\/bmjopen-2023-076518","volume":"14","author":"C McDonald","year":"2024","unstructured":"McDonald C, Alderson C, Birkbeck MG, Brown L, Del Din S, Gorman GG, et al. A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults. BMJ Open. 2024;14(2):e076518.","journal-title":"BMJ Open"},{"key":"2844_CR43","doi-asserted-by":"publisher","unstructured":"Abouhajar A, Alcock L, Bigirumurame T, Bradley P, Brown L, Campbell I et al. Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. Trials [Internet]. 2022 Sept 20 [cited 2025 Oct 29];23(1). Available from: https:\/\/trialsjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13063-022-06544-x","DOI":"10.1186\/s13063-022-06544-x"},{"issue":"3","key":"2844_CR44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s00125-013-3127-2","volume":"57","author":"E Phielix","year":"2014","unstructured":"Phielix E, Jelenik T, Nowotny P, Szendroedi J, Roden M. Reduction of non-esterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: a randomised clinical trial. Diabetologia. 2014;57(3):572\u201381.","journal-title":"Diabetologia"},{"key":"2844_CR45","doi-asserted-by":"crossref","unstructured":"Ying H, Gao L, Liao N, Xu X, Yu W, Hong W. Association between niacin and mortality among patients with cancer in the NHANES retrospective cohort. BMC Cancer [Internet]. 2022 Nov 14 [cited 2025 Dec 5];22(1). Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10265-4.","DOI":"10.1186\/s12885-022-10265-4"},{"issue":"11","key":"2844_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11892-015-0665-7","volume":"15","author":"RK Jain","year":"2015","unstructured":"Jain RK, Laiteerapong N. Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. Curr Diab Rep. 2015;15(11):98.","journal-title":"Curr Diab Rep"},{"key":"2844_CR47","doi-asserted-by":"crossref","unstructured":"Landray MJ, Haynes R, Hopewell JC, et al. Effects of extendedrelease niacin with laropiprant in high-risk patients. N Engl JMed. 2014;371(3):203\u201312.","DOI":"10.1056\/NEJMoa1300955"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02844-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:21:55Z","timestamp":1770124915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-025-02844-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02844-8","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Clinical Research Ethics Committee of the Second Hospital of Tianjin Medical University (KY2023052-01), which waived the requirement for informed patient consent. Written informed consent for participation was not required for this retrospective analysis in accordance with the national legislation and the institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}